Avita Medical Ltd (RCEL)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $491.10M
Last updated: Nov 17, 2026 at 11:05 AM ET
Avita Medical Ltd (RCEL) Stock Forecast
Analysts expect Avita Medical (RCEL) to earn $0.42 per share in the fiscal year ending Dec 31, 2026, on revenue of $134.72M. Of 3 analysts, 3 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 3 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a profit to a loss and revenue estimates rise 21.9%.
- Fiscal year ending Dec 31, 2026
- $0.42
- EPS consensus, revenue $134.72M
- Fiscal year ending Dec 31, 2027
- -$0.32
- EPS consensus, revenue $164.29M
- Next report
- Feb 10, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.42 | -$1.34 to $1.48 | 3 | $134.72M | $132.19M to $136.44M | 6 |
| Dec 31, 2027 | -$0.32 | -$0.55 to $0.11 | 3 | $164.29M | $154.04M to $173.05M | 6 |
Quarterly Estimates
The EPS consensus falls from -$0.20 for the quarter ending Dec 31, 2026 to -$0.26 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.20 | -$0.22 to -$0.18 | 6 | $26.21M | $24.40M to $27.72M | 5 |
| Mar 31, 2027 | -$0.26 | -$0.31 to -$0.22 | 2 | $36.20M | $35.21M to $38.51M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 9 upward and 3 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 4 | 2 |
| Fiscal year ending Dec 31, 2027 | 3 | 1 |
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 425.0% from $0.08.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.42 | $0.25 | $0.25 | $0.25 | $0.08 | +449.5% |
| Fiscal year ending Dec 31, 2027 | -$0.32 | -$0.60 | -$0.60 | -$0.60 | -$0.61 | N/A |
| Quarter ending Mar 31, 2027 | -$0.26 | -$0.26 | -$0.26 | -$0.26 | -$0.26 | N/A |
Frequently Asked Questions About RCEL
What is the RCEL stock forecast?
Consensus analyst estimates put Avita Medical's EPS at $0.42 for the fiscal year ending Dec 31, 2026, on revenue of $134.72M. The consensus rating from 3 analysts is Buy.
How do analysts rate RCEL stock?
Of 3 analysts covering Avita Medical, 0 rate it Strong Buy, 3 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from RCEL next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.42, with estimates from -$1.34 to $1.48 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.32, with estimates from -$0.55 to $0.11 from 3 analysts.
What revenue do analysts expect from Avita Medical next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $134.72M, with estimates from $132.19M to $136.44M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $164.29M, with estimates from $154.04M to $173.05M.
How many analysts cover RCEL?
3 analysts rate Avita Medical stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
RCEL pages: Overview, Earnings, Forecast, Competitors